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INTRODUCTION:  Since  1961  the  use of  Cation  Exchange  Resins  has  been  the  mainstream  treatment  for
chronic  hyperkalemia.  For  the past  25  years  different  kind  of  complications  derived from  its clinical  use
have  been  recognized,  being  the  colonic  necrosis  the  most  feared  and  lethal  of  all.
PRESENTATION  OF CASE:  We  report  a  case  of  a  72-year-old  patient  with  chronic  kidney  disease,  treated
with  calcium  polystyrene  sulfonate  for  hyperkalemia  treatment  who  presented  in  the  emergency
department  with  constipation  treated  with  hypertonic  cathartics.  With  clinical  deterioration  48  h  later
progressed  with  colonic  necrosis  requiring  urgent  laparotomy,  sigmoidectomy  and  open  abdomen  man-
agement  with  subsequent  rectal  stump  perforation  and  dead.  The  histopathology  ﬁnding:  calcium
polystyrene  sulfonate  embedded  in  the  mucosa,  consistent  with  the  cause  of perforation.
DISCUSSION:  Lillemoe  reported  the  ﬁrst  case  series  of ﬁve  uremic  patients  with  colonic  perforation  asso-
ciated  with  the  use  of  SPS  in sorbitol  in  1987  and  in 2009  the  FDA  removed  from  the  market  the  SPS
containing  70%  of sorbitol.
The  pathophysiologic  change  of CER goes  from  mucosal  edema,  ulcers,  pseudomembranes,  and  the
most  severe  case  transmural  necrosis.
Up to present  day,  some  authors  have  questioned  the  use of  CER in  the  setting  of  lowering  serum
potassium.  Despite  its worldwide  use  in  hyperkalemia  settings,  multiple  studies  have  not  demonstrated
a signiﬁcant  potassium  excretion  by  CER.
CONCLUSION:  Despite  the  low  incidence  of colonic  complication  and  lethal  colonic  necrosis  associated
with  the  CER  clinical  use,  the  general  surgeon  needs  a high  index  of  suspicion  when  dealing  with  patients
treated  with  CER  and  abdominal  pain.
© 2015  The  Authors.  Published  by  Elsevier  Ltd. on behalf  of Surgical  Associates  Ltd.  This  is an  open
he CCaccess  article  under  t
. Introduction
Hyperkalemia is a well known complication in patient with
hronic kidney disease, its life threating if unrecognized and
ntreated, this pathophysiological entity is encounter by internists,
ntensivists, nephrologists an emergency department physicians
1].
Since 1961 the use of Cation Exchange Resins (CER) has been the
ainstream of chronic hyperkalemia treatment [2]. For the past 25
ears different kind of complications derived from its clinical use
ave been recognized, being the intestinal obstruction and colonic
ecrosis the most feared and lethal of all. In this setting, the general
nd acute care surgeons joined the specialists listed before in the
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emergency management of these patients. We  present a review
of CER along with the clinical case of a 74-year-old woman with
chronic kidney disease treated with calcium polystyrene sulfonate
(CPS) (Novefazol Probiomed, S.A de C.V. México) seen at emergency
room with uremia and abdominal pain.
2. Case report
A 72-year-old-woman was admitted to the emergency depart-
ment for uremic syndrome, hemodynamic instability and chronic
abdominal pain associated with constipation for 2 weeks. She
had a history of nephrectomy and chronic renal failure with-
out replacement therapy of renal function and hypertension. She
was treated with telmisartan–hydrochlorothiazide, amlodipine
and furosemide.
Three weeks before the current admission she was on treatment
for hyperkalemia with calcium polystyrene sulfonate PO 29.92 g
daily.
iates Ltd. This is an open access article under the CC BY-NC-ND license (http://
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aig. 1. Abdominal CT scan obtain in the second day of hospital stay in the ICU
howing free intraperitoneal air (white arrow) consistent with colonic perforation.
At the emergency department she was treated with polyethy-
ene glycol powder for oral solution 4 l at conventional dilution,
nd rectal enemas with buffered sodium phosphate solution for
onstipation treatment.
She was admitted to the ICU with metabolic acidosis and uremia
xacerbation requiring hemodialysis in the next 48 h.
One day after the admission to the ICU the abdominal distension
ugmented. Abdominal CT shows free intraperitoneal air consistent
ith colonic perforation (Fig. 1).
The patient went to exploratory laparotomy where a perforation
t the sigmoid colon was found (Fig. 2). A Hartmann procedure was
Fig. 2. Sigmoid colon. Transmural necrosis (white arrow).Fig. 3. Sigmoidectomy specimen stained with Haematoxylin–Eosin. Small
basophilic angulated crystals (black arrow) embedded in mucosa consisted with
calcium polystyrene sulfonate related colonic perforation.
performed and open abdomen protocol was  initiated with Open
Abdomen Negative Pressure Therapy with ABThera (KCI) in the
need for a “second look” surgery. Forty-eight hours later, the rectal
stump was found necrotic and a rectal resection on the superior
third of rectum was  perfomed.
Microscopically examination revealed areas of transmural
necrosis in sigmoid colon and rectal stump of heterogeneous dis-
tribution and acute peritonitis with small basophilic angulated
crystals embedded in the mucosa (Fig. 3). There was no evidence of
recent vascular thrombosis. The ﬁnal diagnosis was colonic necrosis
due to CPS associated with hypertonic cathartic use.
3. Discussion
The CER was  ﬁrst synthesized in 1935 and in late 1950s became
available in the open market. Its hypokalemic properties were rec-
ognized until 1961, when its clinical use was  ﬁrst described. In 1975
it gained the US federal approval for hyperkalemia treatment [2].
The ﬁrst CER used was the sodium polystyrene sulfonate (SPS).
The complications derived from the sodium overload in patients
with chronic kidney disease (CKD) led to the use of alternative salts
containing Aluminum and Calcium instead.
Until today, there exists only two therapeutic approaches
approved by FDA to eliminate potassium from the body besides
hemodialysis: Diuretics and CER [3]. In an era where chronic
hemodialysis was not available, different therapies were sought
to deal with such a complex problem. The use of laxatives and
cathartics in order to achieve potassium excretion is an historical
example. Phenolphthalein and sorbitol were the main compounds
used with such purpose. The combination of CER and sorbitol had
its origins based on these grounds [4]. In alleviating constipation
secondary to CER use, its combination with sorbitol gain popularity
in 1997 [5].
In 1987 Lillemoe et al. ﬁrst reported that sorbitol enema leads
to intestinal complications, being the most severe the colonic
necrosis. Their data suggested that the addition of sorbitol is an
important factor for mucosal toxicity. In patients with concomitant
use of kayexalate and sorbitol, only 0.27–1.8% developed intestinal
injuries in the following 1–7 days [6]. In 2009 the FDA removed
from the market the SPS containing 70% of sorbitol and a intro-
duce black-box warning in 33% SPS in sorbitol solution pointing
that is associated with colonic necrosis and serious gastrointestinal
adverse reactions [7].
CER is currently administered orally or as an enema, acting in
the large intestine by extracting and collecting potassium in the
stools, so it can be eliminated, although the exact mechanism for
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his is still under debate [8]. Some authors believe that CER exerts
ts action directly in the ileal and colonic lumen binding potassium
o the stools which is eliminated from the body. As an additional
ffect, CER can bind calcium ions resulting in fecal impaction and
owel obstruction. Other authors suggest a more complex mecha-
ism: In the acid milieu of the stomach, CER’s cations are released
rom the resin binding hydrogen ions. In the large intestine, hydro-
en ions are exchanged for potassium ions, which are eliminated
n the stool [9]. From the second theory one could argue against
nema administration, as CER require their transformation in the
oregut before they can exchange potassium effectively in the mid
nd hindgut [10]. When SPS is given orally (30 g) or rectal (60 g),
ts hypokalemic effect and timing are variable and can take up to
0 h to achieve the desire hypokalemic effect. Most cases of colonic
ecrosis has been reported from hours to days after administration
f SPS with doses ranging from 20 g to 60 g daily [11].
Sorbitol is the most used and FDA approved cathartic in con-
unction with CER mixed in a 33% solutiol. It is metabolized by
olonic bacteria into short-chain fatty acids. If the concentration
f these acids exceeds the patient’s absorption capacity, there is
n osmotic entrance of ﬂuid into the gastrointestinal lumen pro-
ucing osmotic ischemia [12]. Hutchins’s work demonstrated that
noculated tissue with sodium polystyrene sulfonate leads to the
evelopment of an acute inﬂammatory reaction within 24 h, the
roduction of inﬂammatory cytokines and prostaglandins may  lead
o further impairment in local hemodynamic mechanisms leading
o vascular injury and subsequent mucosal injury [13].
The gastrointestinal adverse effects including colonic perfora-
ion have been documented in both type of resins sodium and
alcium polystyrene sulfonate and both in the setting with sor-
itol or alone [14]. The pathophysiologic change of mucosa exposed
o CER ranges from mucosal edema, ulcers, pseudomembranes,
nd the most severe case transmural necrosis. CER can be seen in
istopatological specimens; crystals detected microscopically can
e diagnostic in colonic perforation of unknown origin. SPS crys-
als on Hematoxylin–Eosin stain, appear as basophilic polygonal
rystals; they stain magenta on periodic acid–Schiff and with acid-
ast stain [15]. CPS crystal appearance do not differ from its sodium
ounterpart [16].
At the beginning SPS was only associated with intestinal com-
lications in the setting of patients with multiple comorbidities,
uch as advance renal disease, renal transplant patients, postsurgi-
al patients and hypovolemic in which the intestinal transit was
iminished and the time in which the resin and the intestinal
ucosa contact is prolonged and activation of renin-angiotensin
ystem cause vasospasm of the mesenteric vessels leading to a non
bstructive mesenteric isquemia and intestinal necrosis. The true
echanism remains unclear [17]. sorbitol-free SPS still carry risk
18].
. Conclusion
SPS has been extensively used for the treating hyperkalemia
ithout the imprimatur of a randomized clinical trial regarding its
fﬁcacy and safety, SPS (oral or enema) either alone or with other
herapy. It is often administered in the style of a cookbook recipe
or all the degree of hyperkalemia.
Despite the low incidence of colonic complication and lethal
olonic necrosis associated with the CER clinical use, the general
urgeon needs a high index of suspicion when dealing with patients
reated with CER and abdominal pain in a emergency care setting.
urrently there is no data derived from prospective randomized
linical trials that could guide us in the setting of patients present-
ng constipated or perforated as a complication of the CER use, but
ur understanding of the pathophysiology has grown gradually asPEN  ACCESS
of Surgery Case Reports 16 (2015) 102–105
we have recognized the importance of this issue. No other cathartics
besides sorbitol has been evaluated in conjunction with CER, but we
should use basic clinical reasoning in order to treat such patients.
The ﬁrst thing that we should do is to stop the CER administration
and start hemodynamic and metabolic resuscitation, correcting
hydroelectolyte disturbances speciﬁcally to prevent gastrointesti-
nal hypoperfusion that could lead to transmural necrosis. The use
of other osmotic cathartics should also be avoided. In the setting of
free perforation to abdomino-pelvic cavity, the surgeon must seek
the removal of CER crystals from the peritoneum and the use of on-
table colonic lavage could be used to resolve the crystal impaction.
The creation of a primary anastomosis is ill-adviced and the need
for surgical reexploration is a must as new intestinal perforations
could arise from CER intraluminal or peritoneal remains.
As there is no other treatment for ambulatory hyperkalemia
treatment, the surgeon needs a high index of suspicion for detect-
ing and effectively treat the gastrointestinal complications due CER
clinical use. New compounds for hyperkalemia treatment are being
developed such as patiromer (formerly called RLY5016) and sodium
zirconium cyclosilicate (ZS-9); none of them are currently approve
by de FDA [19,20].
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